Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Added Cholesterol Clear all

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 181
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more

Conditions: Non-Alcoholic Fatty Liver Disease, Obesity
Interventions: Moderately carbohydrate-restricted diet, Fat-restricted diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 10 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mild Cognitive Impairment, Dementia, Mild
Interventions: Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management; Dietary Supplement · Combination Product · Behavioral
Lead sponsor: Alzheimer's Prevention and Reversal Project, Inc.; Other
Eligibility: 45 Years to 76 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Folsom, California • San Rafael, California • Walnut Creek, California + 3 more

Conditions: Stroke
Interventions: Standard, Incentive, Salience, Incentive + Salience; Behavioral
Lead sponsor: Indiana Institute for Medical Research; Other
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hyperlipidemia
Interventions: LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Madison, Wisconsin

Conditions: High Cholesterol, Coronary Artery Disease
Interventions: Ezetimibe, Atorvastatin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Employee Health and Well-being
Interventions: Workplace Wellness Program, Biometric Screening/HRA - No Compensation, Biometric Screening/HRA - Moderate Compensation, Biometric Screening/HRA - High Compensation, Wellness Activities - Low Compensation, Wellness Activities - High Compensation; Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 4,834 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: The Complete Health Improvement Program; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 389 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Hypercholesterolemia
Interventions: pravastatin tablets and Welchol tablets, pravastatin tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 15
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 12 more

Conditions: Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Phone Counseling, Standard Clinical Care; Behavioral · Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 17 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Obesity, Hypercholesterolemia, Cardiovascular Disease
Interventions: Plant-Based Diet, American Heart Association Diet, Mediterranean Diet; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 9 Years to 18 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dyslipidemia
Interventions: Slo-Niacin, atorvastatin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Oxepa, Jevity 1.5, Jevity 1.0; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 13
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 10 more

Conditions: Cardiovascular Disease, Hypercholesterolemia, Obesity, Fatty Liver
Interventions: American Heart Association Diet, Reduced Fat Vegan Diet; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 9 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes
Interventions: Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: New York, New York

Conditions: Dyslipidemia
Interventions: Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions: bempedoic acid, placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more

Conditions: Dyslipidemia
Interventions: Motivational Interviewing (MINT), Usual Care; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and atorvastatin tablets, colesevelam HCl placebo tablets and atorvastatin tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 13
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 10 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Cardiovascular Outcomes
Interventions: Niaspan, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: The Complete Health Improvement Program; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: Not listed
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Athens, Ohio

Search by objective public record fields.

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

MINDSPACE Strategy for Risk Optimization

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

Ezetimibe in Patients Hypo-responsive to Statins

Illinois Workplace Wellness Study

Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

Nurse Telephone Management of Cholesterol in Diabetes

Plant-Based, American Heart Assoc. or Mediterranean Diets In 9-18 yo With BMI >95%, Cholesterol >169 and Their Parents

SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia

High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Improving Adherence to Statins Among Minority Populations

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Benefit of Elevation of HDL-C in Women

Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database